Government-Owned Inventions; Availability for Licensing, 19895-19896 [2021-07709]

Download as PDF jbell on DSKJLSW7X2PROD with NOTICES Federal Register / Vol. 86, No. 71 / Thursday, April 15, 2021 / Notices Date: June 30, 2021. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W238, Rockville, Maryland 20850, (Telephone Conference Call). Contact Person: Byeong-Chel Lee, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W238, Rockville, Maryland 20850, 240–276–7755, byeong-chel.lee@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Research Specialist Award. Date: July 1, 2021. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850, (Telephone Conference Call) Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850, 240–276–6372, zouzhiq@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Training Grant SEP. Date: July 1, 2021. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W234, Rockville, Maryland 20850, (Telephone Conference Call) Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Rockville, Maryland 20850, 240–276–6368, Stoicaa2@mail.nih.gov Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–6: NCI Clinical and Translational Cancer Research. Date: July 9, 2021. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W608, Rockville, Maryland 20850, (Telephone Conference Call) Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W608, Rockville, Maryland 20850, 240–276–5856 nadeem.khan@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology VerDate Sep<11>2014 17:35 Apr 14, 2021 Jkt 253001 Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 12, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–07745 Filed 4–14–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Minority Health and Health Disparities; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be held as a virtual meeting and is open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Minority Health and Health Disparities. Date: May 24, 2021. Closed: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Name of Committee: National Advisory Council on Minority Health and Health Disparities. Date: May 25, 2021. Open: 11:00 a.m. to 4:00 p.m. Agenda: Opening Remarks, Administrative Matters, Director’s Report, Presentations, and Other Business of the Council. Place: National Institutes of Health, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Thomas M. Vollberg, Sr., Ph.D., Director, Office of Extramural Research Administration, National Institute PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 19895 on Minority Health and Health Disparities, National Institutes of Health, 6707 Democracy Boulevard, Suite 800, Bethesda, Maryland 20892–5465, 301–402–1366, Thomas.Vollberg@nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: NIMHD: https://www.nimhd.nih.gov/about/advisorycouncil/, where an agenda and any additional information for the meeting will be posted when available. Dated: April 9, 2021. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–07710 Filed 4–14–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. SUMMARY: FOR FURTHER INFORMATION CONTACT: Dawn Taylor-Mulneix at 301–767–5189 or dawn.taylor-mulneix@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: Technology description follows: E:\FR\FM\15APN1.SGM 15APN1 19896 Federal Register / Vol. 86, No. 71 / Thursday, April 15, 2021 / Notices Human Monoclonal and Bispecific Antibodies Targeting SARS–CoV–2 Coronavirus Description of Technology SARS–CoV–2 is a virus of the Coronavirus family that has emerged as a major public health concern. The first cases of SARS–CoV–2 were reported in China and rapidly spread worldwide leading to a global pandemic. The highest morbidity and mortality have been reported in the elderly and immunocompromised. Antibody therapeutics have great importance for advanced cases of SARS–CoV–2 where a vaccine would not be effective and may be more effective than a vaccine in certain high-risk populations. Scientists at NIAID have developed recombinant monoclonal antibodies that are effective in vitro and in vivo at neutralizing SARS–CoV–2. Based on whether they are mono-specific or bispecific and where they bind to the SARS–CoV–2 virus, these antibodies can be subdivided into four groups that target (A) the receptor-binding-domain (RBD) of the SARS–COV–2 spike protein, (B) the N-terminal domain (NTD) of the SARS–COV–2 spike protein, (C) dual locations on the RBD, or (D) both the RBD and NTD. Crucially, these antibodies effectively neutralize the emerging B.1.1.7 and B.1.351 SARS– CoV–2 variants of concern. These recombinant monoclonal antibodies can be used alone, in combination, or with other therapeutics for the treatment of SARS–COV–2. In addition to their potential as therapeutics, these antibodies against SARS–CoV–2 can be used as prophylactics and in assay development. They can contribute to the surveillance, diagnosis, and prevention of SARS–COV–2. Furthermore, the specific antibody sequences and targets will inform vaccine development and establishment of long-term immunity. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. jbell on DSKJLSW7X2PROD with NOTICES Potential Commercial Applications • Prophylaxis or therapeutics against SARS–CoV–2. • Diagnostics and surveillance of SARS–CoV–2. • Vaccine research. Competitive Advantages • Potent neutralizing activity against SARS–CoV–2, including against B.1.1.7 and B.1.351 variants. VerDate Sep<11>2014 17:35 Apr 14, 2021 Jkt 253001 • Prophylactic usage against SARS– CoV–2 in normal or high-risk populations. • Therapeutic treatment, alone or in combination, in patients with SARS– CoV–2 infection. • Assay development for surveillance, diagnostic, and prevention measures. • Identification of vaccine candidates which elicit protective antibodies against SARS–CoV–2 infections. Development Stage • Pre-clinical. Inventors: Joshua Tan, Ph.D., Peter Crompton, M.D., Hyeseon Cho, Ph.D., Mary Peterson, Kristina Kay GonzalesWartz, Ph.D., all of NIAID. Publications: Cho, Hyeseon, et al. ‘‘Ultrapotent bispecific antibodies neutralize emerging SARS–CoV–2 variants.’’ bioRxiv 2021.04.01.437942; Intellectual Property: HHS Reference No. E–030–2021–0; US provisional application No. 63/127,077 filed on December 17, 2020. Licensing Contact: To license this technology, please contact Dawn TaylorMulneix 301–767–5189 or dawn.taylormulneix@nih.gov, and reference E–030– 2021–0. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Dawn Taylor-Mulneix at 301– 767–5189 or dawn.taylor-mulneix@ nih.gov. Dated: April 7, 2021. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2021–07709 Filed 4–14–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Biobehavioral and Behavioral Sciences Subcommittee. Date: June 28, 2021. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: NICHD Offices, 6710B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Clay Mash, Ph.D., Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, Rm. 2131A, Bethesda, MD 20892, (301) 496–6866, mashc@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: April 12, 2021. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–07735 Filed 4–14–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Instrumentation and Systems Development Study Section. Date: June 17–18, 2021. E:\FR\FM\15APN1.SGM 15APN1

Agencies

[Federal Register Volume 86, Number 71 (Thursday, April 15, 2021)]
[Notices]
[Pages 19895-19896]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-07709]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Dawn Taylor-Mulneix at 301-767-5189 or 
[email protected]. Licensing information may be obtained by 
communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

[[Page 19896]]

Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 
Coronavirus

Description of Technology

    SARS-CoV-2 is a virus of the Coronavirus family that has emerged as 
a major public health concern. The first cases of SARS-CoV-2 were 
reported in China and rapidly spread worldwide leading to a global 
pandemic. The highest morbidity and mortality have been reported in the 
elderly and immunocompromised. Antibody therapeutics have great 
importance for advanced cases of SARS-CoV-2 where a vaccine would not 
be effective and may be more effective than a vaccine in certain high-
risk populations.
    Scientists at NIAID have developed recombinant monoclonal 
antibodies that are effective in vitro and in vivo at neutralizing 
SARS-CoV-2. Based on whether they are mono-specific or bi-specific and 
where they bind to the SARS-CoV-2 virus, these antibodies can be 
subdivided into four groups that target (A) the receptor-binding-domain 
(RBD) of the SARS-COV-2 spike protein, (B) the N-terminal domain (NTD) 
of the SARS-COV-2 spike protein, (C) dual locations on the RBD, or (D) 
both the RBD and NTD. Crucially, these antibodies effectively 
neutralize the emerging B.1.1.7 and B.1.351 SARS-CoV-2 variants of 
concern.
    These recombinant monoclonal antibodies can be used alone, in 
combination, or with other therapeutics for the treatment of SARS-COV-
2. In addition to their potential as therapeutics, these antibodies 
against SARS-CoV-2 can be used as prophylactics and in assay 
development. They can contribute to the surveillance, diagnosis, and 
prevention of SARS-COV-2. Furthermore, the specific antibody sequences 
and targets will inform vaccine development and establishment of long-
term immunity.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     Prophylaxis or therapeutics against SARS-CoV-2.
     Diagnostics and surveillance of SARS-CoV-2.
     Vaccine research.

Competitive Advantages

     Potent neutralizing activity against SARS-CoV-2, including 
against B.1.1.7 and B.1.351 variants.
     Prophylactic usage against SARS-CoV-2 in normal or high-
risk populations.
     Therapeutic treatment, alone or in combination, in 
patients with SARS-CoV-2 infection.
     Assay development for surveillance, diagnostic, and 
prevention measures.
     Identification of vaccine candidates which elicit 
protective antibodies against SARS-CoV-2 infections.

Development Stage

     Pre-clinical.
    Inventors: Joshua Tan, Ph.D., Peter Crompton, M.D., Hyeseon Cho, 
Ph.D., Mary Peterson, Kristina Kay Gonzales-Wartz, Ph.D., all of NIAID.
    Publications: Cho, Hyeseon, et al. ``Ultrapotent bispecific 
antibodies neutralize emerging SARS-CoV-2 variants.'' bioRxiv 
2021.04.01.437942;
    Intellectual Property: HHS Reference No. E-030-2021-0; US 
provisional application No. 63/127,077 filed on December 17, 2020.
    Licensing Contact: To license this technology, please contact Dawn 
Taylor-Mulneix 301-767-5189 or [email protected], and 
reference E-030-2021-0.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact Dawn Taylor-Mulneix at 301-767-5189 or 
[email protected].

    Dated: April 7, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-07709 Filed 4-14-21; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.